Exploring the regulatory framework of psychedelics in the US & Europe.

导出 LinkOut

翻译打印收藏纠错

作者： Hitesh Kumar,Behera ^[1] ; Ramesh,Joga ^[1] ; Sravani,Yerram ^[1] ; Praveena,Karnati ^[1] ; Tejaswini,Mergu ^[1] ; Kajal,Gandhi ^[1] ; Sowndharya,M ^[1] ; Deepak,Nathiya ^[2] ; Ravindra Pal,Singh ^[3] ; Saurabh,Srivastava ^[4] ; Sandeep,Kumar ^[5]

作者单位： Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India. ^[1] Department of Pharmacy Practice, Nims Institute of Pharmacy, Nims University Rajasthan, Jaipur, Rajasthan 303121, India. ^[2] Department of Pharmaceutics, Nims Institute of Pharmacy, Nims University Rajasthan, Jaipur, Rajasthan 303121, India. ^[3] Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India. Electronic address: saurabh@niperhyd.ac.in. ^[4] Department of Pharmaceutics, Nims Institute of Pharmacy, Nims University Rajasthan, Jaipur, Rajasthan 303121, India. Electronic address: ssandeepkatarea@gmail.com. ^[5]

关键词 DMT Ketamine LSD Law MDMA Magic mushrooms Mescaline Policy Psilocybin Psychedelics Regulatory

主题词人类(Humans);药物批准(Drug Approval);欧洲(Europe);致幻药(Hallucinogens);美国(United States);美国食品和药物管理局(United States Food and Drug Administration)

DOI 10.1016/j.ajp.2024.104242

PMID 39305768

发布时间 2024-12-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交